LFVN
LifeVantage Corporation6.33
-0.12-1.86%
Dec 16, 4:00:02 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
FY Q2 '26
Q&A details MINDBODY tactics, LoveBiome ramps
Q&A fleshed out MINDBODY revival tactics—20% discounts through February, Activate Ninety events, new app tracking, and win-back campaigns—amid stabilized demand into weight-loss season. LoveBiome details emerged: $3.7M cash purchase plus earn-out, $4M Q2 product revenue, recent Axio X and Phytopower B launches with ~1,000 kickoff attendees, more coming. Inventory reserve traced to post-launch overbuild; execs defended natural GLP-1 edge over synthetics. H2 revenue builds Q3 to Q4 on LoveBiome integration. Analysts pressed GLP-1 viability and charge; answers stayed optimistic yet tactical. Q&A adds execution color to prepared challenges. LoveBiome delivers.
Key Stats
Market Cap
80.40MP/E (TTM)
8.12Basic EPS (TTM)
0.78Dividend Yield
0.03%Recent Filings
10-Q
Q2 FY2026 results
LifeVantage revenue fell 27.8% y/y to $48.9M in Q2 FY2026 ended December 31, 2025, yet swung to $0.5M operating income from prior-year $3.4M while gross margin held at 74.0% despite MindBody GLP-1 sales drop and $2.4M inventory obsolescence. Commissions plunged 38.9% y/y to $19.9M (40.7% of revenue), trimming op-ex; diluted EPS matched $0.02 on 12,745k shares with no anti-dilution. Cash dipped to $10.2M after $3.7M LoveBiome asset buy (Oct 2025, $0.5M goodwill, $3.2M intangibles over 5-7 years), $0.5M op cash vs $8.6M y/y, $5M revolver undrawn. Active accounts shrank 21%. Loves its consultants. But consultant retention lags.
8-K
Q2 revenue plunges; CEO retiring
LifeVantage reported Q2 fiscal 2026 revenue of $48.9 million, down 27.8% year-over-year amid MindBody GLP-1 sales slump post-launch and $2.4 million inventory obsolescence charge; yet Adjusted EBITDA held at $3.9 million. CEO Steve Fife to retire in April 2026—no disagreements noted. Board approved $60 million share repurchase through 2027. Guidance eyes $185-200 million full-year revenue.
8-K
Two C-level resignations
LifeVantage's Chief Marketing Officer Julie Boyster and Chief Information and Innovation Officer Todd Thompson announced resignations on December 3, 2025, effective December 12 and December 24, respectively, to pursue other opportunities. No successors named yet. Leadership shakeup hits marketing and tech innovation.
8-K
Annual meeting results approved
LifeVantage stockholders convened their fiscal 2026 annual meeting on November 6, 2025, with 75.41% of shares present. All seven director nominees sailed through election despite some pushback on four; exec pay won advisory approval, Deloitte ratification passed overwhelmingly, and the 2017 LTIP amendment cleared narrowly at 5.4M for versus 2.3M against. Board continuity locked in.
10-Q
Q1 FY2026 results
LifeVantage posted steady Q1 FY2026 revenue of $47.6M, up 0.7% y/y from $47.2M yet down q/q from prior quarter, with gross margins dipping to 79.5% from 79.9% y/y on higher shipping costs; operating income slipped to $2.3M from $2.6M while net income climbed 18% to $2.2M or $0.17 diluted EPS, reconciled to 12.9M shares. U.S. held 74% of sales at $35.2M (flat y/y), Japan grew 3.5% to $6.2M, fueled by MindBody GLP-1 launches, but Protandim and TrueScience declined. Cash fell to $13.1M after $2.3M operating outflow, $0.6M buybacks, and $0.6M dividends, with $5M revolver fully available (no debt). Closed LoveBiome asset purchase Oct 1. Active accounts drive growth, yet consultant retention poses risks.
IPO
Website
Employees
Sector
Industry
BFNH
BioForce Nanosciences Holdings,
0.60+0.07
BHST
BioHarvest Sciences Inc.
5.50+0.30
FTLF
FitLife Brands, Inc.
18.10-0.28
GWLL
GOLDENWELL BIOTECH INC
3.00+0.00
HLF
Herbalife Ltd.
14.45-0.45
LIMX
Limitless X Holdings Inc.
1.40+0.00
LSF
Laird Superfood, Inc.
2.07+0.05
NATR
Nature's Sunshine Products, Inc
22.38-0.85
USNA
USANA Health Sciences, Inc.
20.33+0.01
XAGE
Longevity Health Holdings, Inc.
0.44-0.05